Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002817 | 0.84 | MAPK14 (0.35) | MAPK14SCN9AGRM2HCRTR1ULK1 | |
| SCHEMBL4762646 | 0.75 | TSHR (0.34) | MAPK14SCN9AGRM2HCRTR1ULK1 | |
| SCHEMBL4877480 | 0.68 | HCRTR1 (0.36) | MAPK14HCRTR1HCRTR2 | |
| SCHEMBL4868024 | 0.66 | TAAR1 (0.36) | MAPK14HCRTR1HCRTR2 | |
| SCHEMBL4762449 | 0.65 | HCRTR1 (0.34) | MAPK14SCN9AHCRTR1ULK1HCRTR2 | |
| SCHEMBL14705600 | 0.64 | GRM2 (0.43) | SCN9AGRM2 | |
| SCHEMBL6004205 | 0.63 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL6004400 | 0.63 | ULK1 (0.39) | SCN9AGRM2HCRTR1ULK1ACVR1 | |
| SCHEMBL4761322 | 0.62 | KDM4E (0.38) | MAPK14HCRTR1HCRTR2 | |
| SCHEMBL6002812 | 0.58 | ULK1 (0.38) | SCN9AHCRTR1ULK1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | MAPK14 26/4885SCN9A 4676/4885GRM2 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.